Routine vitamin B12, folate and thyroid biomarkers, cognitive trajectory and mortality in older adults with neurocognitive disorders: a retrospective cohort study

Background Vitamin B12, folate and thyroid-function testing are routinely included in dementia workups, but their prognostic significance after a neurocognitive-disorder diagnosis remains uncertain. Methods We analyzed a deidentified Taiwanese tertiary-hospital cohort of patients aged ≥65 years with neurocognitive disorders (dementia or mild cognitive impairment; n = 7,969). The prespecified primary analyses were mixed-effects models of annual MMSE and CDR-SB trajectories in which baseline vitamin B12, folate, TSH and free thyroxine were entered jointly, restricted to patients with all four biomarkers and at least two assessments (MMSE n = 818; CDR-SB n = 1,009). CDR progression and all-cause mortality were secondary outcomes, and prescription-record analyses were exploratory. Sensitivity analyses addressed missing data, selection into the analysis sets, competing risks, confounding, laboratory timing and prior treatment. Results Biomarker testing and repeated cognitive assessment were clinically driven, so all estimates apply to a selected tested-and-followed subgroup that was younger, less impaired and less likely to die than untested or unfollowed patients. Higher baseline vitamin B12 was associated with slower MMSE decline (β +0.146 points/year per SD, 95% CI +0.038 to +0.255; FDR q = 0.017), an association retained after multiple imputation and selection weighting but attenuated after excluding patients treated before baseline. The full-range association of higher TSH with slower decline on both scales was not robust: it depended on a few patients with TSH > 10 mIU/L and was absent within the euthyroid range. Folate deficiency was associated with faster CDR progression (HR 1.57, 95% CI 1.13–2.19, p = 0.008), including in competing-risk models; the estimate for vitamin B12 deficiency was imprecise (HR 1.22, 95% CI 0.88–1.69, p = 0.23) and does not exclude a clinically relevant increase. Higher vitamin B12 was associated with all-cause mortality (HR 1.035 per 100 pg/mL, 95% CI 1.016–1.055), but this was attenuated after flexible adjustment for renal function. Documented vitamin B12 supplementation showed no detectable association with CDR-SB trajectory in a small exploratory matched analysis. Conclusion In patients who underwent biomarker testing and repeated cognitive assessment, routine biomarkers from workups for reversible causes provided modest, context-dependent prognostic information. We interpret these associations as possible indicators of clinical state rather than evidence that the biomarkers, or their correction, influence the progression of neurocognitive disorders.

Authors

Institutions

Publication Details

Journal
Frontiers in Aging Neuroscience
Published
2026-11-17
DOI
https://doi.org/10.3389/fnagi.2026.1933671
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Routine vitamin B12, folate and thyroid biomarkers, cognitive trajectory and mortality in older adults with neurocognitive disorders: a retrospective cohort study

Pei‐Hao Chen, Fang‐Yu Cheng, Kai Lo
1 links
Frontiers in Aging Neuroscience
Dementia and Cognitive Impairment Research
article

Routine vitamin B12, folate and thyroid biomarkers, cognitive trajectory and mortality in older adults with neurocognitive disorders: a retrospective cohort study

Pei‐Hao Chen, Fang‐Yu Cheng, Kai Lo
article en

Abstract

Background Vitamin B12, folate and thyroid-function testing are routinely included in dementia workups, but their prognostic significance after a neurocognitive-disorder diagnosis remains uncertain. Methods We analyzed a deidentified Taiwanese tertiary-hospital cohort of patients aged ≥65 years with neurocognitive disorders (dementia or mild cognitive impairment; n = 7,969). The prespecified primary analyses were mixed-effects models of annual MMSE and CDR-SB trajectories in which baseline vitamin B12, folate, TSH and free thyroxine were entered jointly, restricted to patients with all four biomarkers and at least two assessments (MMSE n = 818; CDR-SB n = 1,009). CDR progression and all-cause mortality were secondary outcomes, and prescription-record analyses were exploratory. Sensitivity analyses addressed missing data, selection into the analysis sets, competing risks, confounding, laboratory timing and prior treatment. Results Biomarker testing and repeated cognitive assessment were clinically driven, so all estimates apply to a selected tested-and-followed subgroup that was younger, less impaired and less likely to die than untested or unfollowed patients. Higher baseline vitamin B12 was associated with slower MMSE decline (β +0.146 points/year per SD, 95% CI +0.038 to +0.255; FDR q = 0.017), an association retained after multiple imputation and selection weighting but attenuated after excluding patients treated before baseline. The full-range association of higher TSH with slower decline on both scales was not robust: it depended on a few patients with TSH > 10 mIU/L and was absent within the euthyroid range. Folate deficiency was associated with faster CDR progression (HR 1.57, 95% CI 1.13–2.19, p = 0.008), including in competing-risk models; the estimate for vitamin B12 deficiency was imprecise (HR 1.22, 95% CI 0.88–1.69, p = 0.23) and does not exclude a clinically relevant increase. Higher vitamin B12 was associated with all-cause mortality (HR 1.035 per 100 pg/mL, 95% CI 1.016–1.055), but this was attenuated after flexible adjustment for renal function. Documented vitamin B12 supplementation showed no detectable association with CDR-SB trajectory in a small exploratory matched analysis. Conclusion In patients who underwent biomarker testing and repeated cognitive assessment, routine biomarkers from workups for reversible causes provided modest, context-dependent prognostic information. We interpret these associations as possible indicators of clinical state rather than evidence that the biomarkers, or their correction, influence the progression of neurocognitive disorders.

Frontiers in Aging NeuroscienceVol. 18
National Taipei University of Technology (TW), Mackay Memorial Hospital (TW), Mackay Medical University (TW), University of Glasgow (GB)
Good health and well-being
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon